Thus, we concluded that metformin treatment reduced the tumor-initiating (self-renewal) capacity of breast epithelial BRCA1 one-hit cells, whereas BRCA1 wild-type cells were mostly resistant at similar doses, which is indicative of a wide therapeutic index. The gene discussed is BRCA1; the disease is neoplasm.